Aptevo Therapeutics Inc.
APVO
$4.78
$0.132.80%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 71.00K | -345.00K | 54.00K | 49.00K | 242.00K |
| Gross Profit | -71.00K | 345.00K | -54.00K | -49.00K | -242.00K |
| SG&A Expenses | 2.85M | 2.50M | 2.11M | 2.38M | 3.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.48M | 6.38M | 5.21M | 6.02M | 6.98M |
| Operating Income | -6.48M | -6.38M | -5.21M | -6.02M | -6.98M |
| Income Before Tax | -6.41M | -6.31M | -5.10M | -5.88M | -6.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.41M | -6.31M | -5.10M | -5.88M | -6.83M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.41M | -6.31M | -5.10M | -5.88M | -6.83M |
| EBIT | -6.48M | -6.38M | -5.21M | -6.02M | -6.98M |
| EBITDA | -6.42M | -6.31M | -5.13M | -5.93M | -6.88M |
| EPS Basic | -87.87 | -154.65 | -357.84 | -- | -- |
| Normalized Basic EPS | -54.92 | -96.65 | -223.65 | -- | -- |
| EPS Diluted | -87.87 | -154.81 | -357.84 | -- | -- |
| Normalized Diluted EPS | -54.92 | -96.65 | -223.65 | -- | -- |
| Average Basic Shares Outstanding | 72.90K | 40.80K | 14.30K | -- | -- |
| Average Diluted Shares Outstanding | 72.90K | 40.80K | 14.30K | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |